Prospective follow-up study of ustekinumab treatment in psoriatic arthritis

Prospective follow-up study of ustekinumab treatment in psoriatic arthritis - Ustekinumab in psoriatic arthritis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40967

Enrollment

Registered

2014-10-15

Start date

2016-01-15

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriatic arthritis rheumatic disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients: - who are diagnosed with psoriatic arthritis; - in whom ustekinumab is prescribed by their treating rheumatologist; and - who gave written informed consent. Both biological naive patients as patients who failed on TNF-blocking agents are included.

Exclusion criteria

Exclusion criteria: Patients with contraindications for ustekinumab treatment.

Design outcomes

Primary

Measure	Time frame
- DAS28 score and response is defined as the EULAR criteria of a good or moderate response and a score of	—

Secondary

Measure	Time frame
- The number of adverse events (infections, malignancies, mortality) - LEI improvement - Number of nails with nail psoriasis - ESR and/or CRP - The lipid profile - Inflammation processes - Relation between genetic polymorphisms and the efficacy of ustekinumab - Radiographic progression - Changes in bone mineral density - Cardiovascular risk factors	—

Countries

Netherlands

Outcome results